Press release
Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Advanced Urothelial Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Advanced Urothelial Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-urotheilal-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Advanced Urothelial Carcinoma Pipeline Report
* In April 2025, Janssen Research & Development LLC conducted a study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.
* DelveInsight's Advanced Urothelial Carcinoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Advanced Urothelial Carcinoma treatment.
* The leading Advanced Urothelial Carcinoma Companies such as Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
* Promising Advanced Urothelial Carcinoma Pipeline Therapies such as SHR-A2102, Adebrelimab injection, Selinexor, Pembrolizumab, 9MW2821, Toripalimab and others.
Stay ahead with the most recent pipeline outlook for Advanced Urothelial Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Urothelial Carcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/advanced-urotheilal-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Urothelial Carcinoma Emerging Drugs Profile
* 9MW2821: Mabwell (Shanghai) Bioscience Co., Ltd.
9MW2821 is a novel Nectin-4 targeting ADC developed by ADC platform and automated high-throughput antibody discovery platform of Mabwell. It boasts the advantages of homogenous structure, high purity and being easy production. It has also demonstrated favorable druggability properties in binding affinity, endocytosis, preliminary in vivo and in vitro pharmacodynamic activities, drug metabolism properties and preliminary safety. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.
* AZD4547: Abbisko Therapeutics Co, Ltd
AZD-4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.
* AUR106: Aurigene Discovery Technologies Limited
AUR106 is an orally bioavailable small molecule inhibitor of the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1, with potential immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, TIGIT/PD-L1 inhibitor AUR-106 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.
The Advanced Urothelial Carcinoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Urothelial Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Urothelial Carcinoma Treatment.
* Advanced Urothelial Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Advanced Urothelial Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Urothelial Carcinoma market
Explore groundbreaking therapies and clinical trials in the Advanced Urothelial Carcinoma Pipeline. Access DelveInsight's detailed report now! @ New Advanced Urothelial Carcinoma Drugs [https://www.delveinsight.com/sample-request/advanced-urotheilal-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Urothelial Carcinoma Companies
Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
Advanced Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Advanced Urothelial Carcinoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Advanced Urothelial Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Advanced Urothelial Carcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/advanced-urotheilal-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Advanced Urothelial Carcinoma Pipeline Report
* Coverage- Global
* Advanced Urothelial Carcinoma Companies- Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd . and others.
* Advanced Urothelial Carcinoma Pipeline Therapies- SHR-A2102, Adebrelimab injection, Selinexor, Pembrolizumab, 9MW2821, Toripalimab and others.
* Advanced Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Advanced Urothelial Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Advanced Urothelial Carcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/advanced-urotheilal-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Advanced Urothelial Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Urothelial Carcinoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* 9MW2821: Mabwell (Shanghai) Bioscience Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* AZD4547: Abbisko Therapeutics Co, Ltd
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AUR106: Aurigene Discovery Technologies Limited
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Urothelial Carcinoma Key Companies
* Advanced Urothelial Carcinoma Key Products
* Advanced Urothelial Carcinoma- Unmet Needs
* Advanced Urothelial Carcinoma- Market Drivers and Barriers
* Advanced Urothelial Carcinoma- Future Perspectives and Conclusion
* Advanced Urothelial Carcinoma Analyst Views
* Advanced Urothelial Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-urothelial-carcinoma-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3959430 • Views: …
More Releases from ABNewswire
Non-Small Cell Lung Cancer Market Positioned for Accelerated Development Through …
The Key Non-Small Cell Lung Cancer Companies in the market include - AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, Merck, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, AstraZeneca, Amgen, Blueprint Medicines/Rigel Pharmaceuticals, and others.
The Non-Small Cell Lung Cancer (NSCLC) market was valued at approximately USD 32 billion in 2025 and…
Vietnamese University Students Publish 'Vietnam Hangeul Newspaper' ... K-Wave No …
Image: https://www.abnewswire.com/upload/2025/10/fe9c4c1c8de543dfef7abbb9c8e22d9d.jpg
Vietnamese youth are attracting attention from Korea and around the world by producing a newspaper written entirely in Hangeul, the Korean alphabet. First launched online in January, the "Vietnam Hangeul Newspaper" is a regular publication created by students from six Vietnamese universities. While it is common for non-English-speaking countries to publish newspapers in English, this marks the world's first instance of local students voluntarily producing a newspaper in Hangeul.
Currently,…
From Culture Kings to Creator Army: Simon Beard Announces New AI Content Venture
Simon Beard, co-founder of Culture Kings, launches Creator Army-an AI-assisted content bootcamp and on-demand marketplace for creators.
Gold Coast, Australia - October 7, 2025 - Serial entrepreneur Simon Beard, best known as the founder of global streetwear retailer Culture Kings, this week announced the forthcoming launch of his latest venture, Creator Army-an AI-assisted content creation platform and on-demand marketplace built to empower the next generation of creators and help businesses access…
Experts Pick SendTurtle in Roundup of Best File Transfer Tools for Security-Cons …
Recognition highlights SendTurtle's unique blend of privacy-first design, AI analytics, and seamless user experience.
Arlington, VA - SendTurtle, the SaaS platform redefining how startups, consultants, and business leaders share documents, today announced that it has been recognized by industry experts in a recent roundup of the best file transfer tools for security-conscious teams. The acknowledgment underscores SendTurtle's rapid rise as the trusted platform for secure, frictionless file sharing with built-in intelligence.
Unlike…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
